Cardiff Oncology's Promising Trial Results in RAS-Mutated Cancer

San Diego, Tuesday, 10 December 2024.
Cardiff Oncology reports a 64% response rate in its Phase 2 trial for RAS-mutated colorectal cancer, marking a potential breakthrough in treatment efficacy and safety.